Global Preimplantation Genetics Diagnosis (PGD) Market is Estimated to Reach $140 Million by 2024, Says Accurize Market Research


Global Preimplantation Genetics Diagnosis (PGD) Market is Estimated to Reach $140 Million by 2024, Says Accurize Market Research

Global Preimplantation Genetics Diagnosis (PGD)Market report published by Accurize Market Research forecast that the global market is expected to reach $140 Million by 2024; growing at a CAGR of 6.2% from 2017 to 2025. By geography, Asia Pacific and North America are expected to grow at a CAGR of XX% and XX%, respectively, during the forecast period.

To browse the complete report, visit at

Increasing occurrence of genetic disorders todrive the global market

Some of the factors driving the growth of the global preimplantation genetics diagnosis (PGD) market are declining fertility rate, advancements in the field of genetic analysis, increasing occurrence of genetic disorders, rising demand of IVF treatments, and high possibility of genetic abnormalities in embryos with progressing maternal age. Factors such as stringent government regulations and social-economic concerns would limit the growth of the market. However, rising R&D and market expansion would provide market opportunities in the coming years.

Market Segmentation

Test type and geography are the major bifurcations in the global preimplantation genetics diagnosis (PGD) market. Test type is further categorized as gender selection, chromosomal abnormalities, single gene disorders, HLA typing, aneuploidy, X-linked diseases, and other test types.

North America, Europe, Asia-Pacific and rest of the world (RoW) are the geographical segments of the market. North America is further bifurcated into countries namely; U.S., Canada and Mexico. Europe covers countries like Russia, U.K., Germany, France, Italy and Rest of Europe. Asia-Pacific countries include China, India, Japan, South Korea and Rest of Asia Pacific. Rest of the World (RoW) covers South America, Africa and Middle East.

"Chromosomal abnormalities accounted for the largest market share in the type segment", says Accurize

Chromosomal abnormalities accounted the largest market share, whereas, other test types shall attain the fastest CAGR during the forecast period 2017–2025.

"North America dominated the global market with the highest market share over the forecast period", says Accurize

Europe and North America accounted the maximum market share in 2017, with 31.5% and 26.8% respectively. In terms of growth, North America would dominate with fastest CAGR during the forecast period, driven by, high awareness among people regarding availability of such treatment, increasing infertility rate, and rising investments by government organizations.

Top players in the market

Major companies operating in the market include Abbott Laboratories, Natera, Inc., PerkinElmer, Inc., Illumina, Inc., F. Hoffmann-La Roche AG, Thermo Fisher Scientific, Inc., Agilent Technologies, Inc., PerkinElmer, Inc., Cooper Surgical, Inc., and Beijing Genomics Institute (BGI), among others.

Contact Us

Stephen Jones,

Head - Sales

Accurize Market Research



Tel: +91-612-2369997